Eli Lilly’s Mounjaro (tirzepatide) won FDA approval to reduce cardiovascular risk, adding a new label that could extend the blockbuster’s reach in cardiometabolic care. In parallel, Teva agreed to buy an approved drug from AusperBio and Samsung Biologics had additional updates mentioned alongside the market news. On epilepsy, SK Biopharmaceuticals agreed to acquire Biohaven’s Kv7 program through a deal tied to opakalim (BHV-7000), a late-stage potassium channel activator. The transaction underscores how commercial infrastructure and pipeline de-risking are driving consolidation in neurology.